What is the projected market valuation of the Retinal Gene Therapy Market by 2035?

The projected market valuation of the Retinal Gene Therapy Market by 2035 is 37.1 USD Billion. Read More

What was the market valuation of the Retinal Gene Therapy Market in 2024?

The market valuation of the Retinal Gene Therapy Market in 2024 was 5.237 USD Billion. Read More

What is the expected CAGR for the Retinal Gene Therapy Market during the forecast period 2025 - 2035?

The expected CAGR for the Retinal Gene Therapy Market during the forecast period 2025 - 2035 is 19.48%. Read More

Which companies are considered key players in the Retinal Gene Therapy Market?

Key players in the Retinal Gene Therapy Market include Novartis, Spark Therapeutics, GenSight Biologics, AGTC, MeiraGTx, Astellas Pharma, Sangamo Therapeutics, Regenxbio, and Applied Genetic Technologies Corporation. Read More

What is the valuation range for Retinitis Pigmentosa in the Retinal Gene Therapy Market?

The valuation range for Retinitis Pigmentosa in the Retinal Gene Therapy Market is projected to be between 1.5 and 10.0 USD Billion. Read More

What gene types are included in the Retinal Gene Therapy Market segments?

Gene types in the Retinal Gene Therapy Market segments include Adeno-Associated Virus, Lentivirus, Messenger RNA, and DNA. Read More

What is the projected valuation for the Adeno-Associated Virus segment by 2035?

The projected valuation for the Adeno-Associated Virus segment by 2035 is expected to be between 1.5 and 10.5 USD Billion. Read More

What administration routes are utilized in the Retinal Gene Therapy Market?

Administration routes utilized in the Retinal Gene Therapy Market include Intravitreal Injection, Subretinal Injection, and Intravitreous Injection. Read More

What is the expected valuation for research laboratories in the Retinal Gene Therapy Market?

The expected valuation for research laboratories in the Retinal Gene Therapy Market is projected to be between 2.617 and 20.1 USD Billion. Read More

Retinal Gene Therapy Market

Q: What are the market segments based on indication in the Retinal Gene Therapy Market?

Market segments based on indication include Leber Congenital Amaurosis, Retinitis Pigmentosa, Stargardt Disease, and Choroideremia. Read More

ID: MRFR/HC/36847-HCR

100 Pages

Nidhi Mandole

Last Updated: April 06, 2026

Retinal Gene Therapy Market Research Report By Indication (Leber Congenital Amaurosis, Retinitis Pigmentosa, Stargardt Disease, Choroideremia), By Gene Type (Adeno-Associated Virus, Lentivirus, Messenger RNA, DNA), By Administration Route (Intravitreal Injection, Subretinal Injection, Intravitreous Injection), By End Use (Hospitals, Specialty Clinics, Research Laboratories) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Healthcare, BY Indication (USD Billion)
  1. 4.1.1 Leber Congenital Amaurosis
  2. 4.1.2 Retinitis Pigmentosa
  3. 4.1.3 Stargardt Disease
  4. 4.1.4 Choroideremia
2. 4.2 Healthcare, BY Gene Type (USD Billion)
  1. 4.2.1 Adeno-Associated Virus
  2. 4.2.2 Lentivirus
  3. 4.2.3 Messenger RNA
  4. 4.2.4 DNA
3. 4.3 Healthcare, BY Administration Route (USD Billion)
  1. 4.3.1 Intravitreal Injection
  2. 4.3.2 Subretinal Injection
  3. 4.3.3 Intravitreous Injection
4. 4.4 Healthcare, BY End Use (USD Billion)
  1. 4.4.1 Hospitals
  2. 4.4.2 Specialty Clinics
  3. 4.4.3 Research Laboratories
5. 4.5 Healthcare, BY Region (USD Billion)
  1. 4.5.1 North America
    1. 4.5.1.1 US
    2. 4.5.1.2 Canada
  2. 4.5.2 Europe
    1. 4.5.2.1 Germany
    2. 4.5.2.2 UK
    3. 4.5.2.3 France
    4. 4.5.2.4 Russia
    5. 4.5.2.5 Italy
    6. 4.5.2.6 Spain
    7. 4.5.2.7 Rest of Europe
  3. 4.5.3 APAC
    1. 4.5.3.1 China
    2. 4.5.3.2 India
    3. 4.5.3.3 Japan
    4. 4.5.3.4 South Korea
    5. 4.5.3.5 Malaysia
    6. 4.5.3.6 Thailand
    7. 4.5.3.7 Indonesia
    8. 4.5.3.8 Rest of APAC
  4. 4.5.4 South America
    1. 4.5.4.1 Brazil
    2. 4.5.4.2 Mexico
    3. 4.5.4.3 Argentina
    4. 4.5.4.4 Rest of South America
  5. 4.5.5 MEA
    1. 4.5.5.1 GCC Countries
    2. 4.5.5.2 South Africa
    3. 4.5.5.3 Rest of MEA
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Healthcare
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Novartis (CH)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Spark Therapeutics (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 GenSight Biologics (FR)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 AGTC (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 MeiraGTx (GB)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Astellas Pharma (JP)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Sangamo Therapeutics (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Regenxbio (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Applied Genetic Technologies Corporation (US)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 NORTH AMERICA MARKET ANALYSIS
3. 6.3 US MARKET ANALYSIS BY INDICATION
4. 6.4 US MARKET ANALYSIS BY GENE TYPE
5. 6.5 US MARKET ANALYSIS BY ADMINISTRATION ROUTE
6. 6.6 US MARKET ANALYSIS BY END USE
7. 6.7 CANADA MARKET ANALYSIS BY INDICATION
8. 6.8 CANADA MARKET ANALYSIS BY GENE TYPE
9. 6.9 CANADA MARKET ANALYSIS BY ADMINISTRATION ROUTE
10. 6.10 CANADA MARKET ANALYSIS BY END USE
11. 6.11 EUROPE MARKET ANALYSIS
12. 6.12 GERMANY MARKET ANALYSIS BY INDICATION
13. 6.13 GERMANY MARKET ANALYSIS BY GENE TYPE
14. 6.14 GERMANY MARKET ANALYSIS BY ADMINISTRATION ROUTE
15. 6.15 GERMANY MARKET ANALYSIS BY END USE
16. 6.16 UK MARKET ANALYSIS BY INDICATION
17. 6.17 UK MARKET ANALYSIS BY GENE TYPE
18. 6.18 UK MARKET ANALYSIS BY ADMINISTRATION ROUTE
19. 6.19 UK MARKET ANALYSIS BY END USE
20. 6.20 FRANCE MARKET ANALYSIS BY INDICATION
21. 6.21 FRANCE MARKET ANALYSIS BY GENE TYPE
22. 6.22 FRANCE MARKET ANALYSIS BY ADMINISTRATION ROUTE
23. 6.23 FRANCE MARKET ANALYSIS BY END USE
24. 6.24 RUSSIA MARKET ANALYSIS BY INDICATION
25. 6.25 RUSSIA MARKET ANALYSIS BY GENE TYPE
26. 6.26 RUSSIA MARKET ANALYSIS BY ADMINISTRATION ROUTE
27. 6.27 RUSSIA MARKET ANALYSIS BY END USE
28. 6.28 ITALY MARKET ANALYSIS BY INDICATION
29. 6.29 ITALY MARKET ANALYSIS BY GENE TYPE
30. 6.30 ITALY MARKET ANALYSIS BY ADMINISTRATION ROUTE
31. 6.31 ITALY MARKET ANALYSIS BY END USE
32. 6.32 SPAIN MARKET ANALYSIS BY INDICATION
33. 6.33 SPAIN MARKET ANALYSIS BY GENE TYPE
34. 6.34 SPAIN MARKET ANALYSIS BY ADMINISTRATION ROUTE
35. 6.35 SPAIN MARKET ANALYSIS BY END USE
36. 6.36 REST OF EUROPE MARKET ANALYSIS BY INDICATION
37. 6.37 REST OF EUROPE MARKET ANALYSIS BY GENE TYPE
38. 6.38 REST OF EUROPE MARKET ANALYSIS BY ADMINISTRATION ROUTE
39. 6.39 REST OF EUROPE MARKET ANALYSIS BY END USE
40. 6.40 APAC MARKET ANALYSIS
41. 6.41 CHINA MARKET ANALYSIS BY INDICATION
42. 6.42 CHINA MARKET ANALYSIS BY GENE TYPE
43. 6.43 CHINA MARKET ANALYSIS BY ADMINISTRATION ROUTE
44. 6.44 CHINA MARKET ANALYSIS BY END USE
45. 6.45 INDIA MARKET ANALYSIS BY INDICATION
46. 6.46 INDIA MARKET ANALYSIS BY GENE TYPE
47. 6.47 INDIA MARKET ANALYSIS BY ADMINISTRATION ROUTE
48. 6.48 INDIA MARKET ANALYSIS BY END USE
49. 6.49 JAPAN MARKET ANALYSIS BY INDICATION
50. 6.50 JAPAN MARKET ANALYSIS BY GENE TYPE
51. 6.51 JAPAN MARKET ANALYSIS BY ADMINISTRATION ROUTE
52. 6.52 JAPAN MARKET ANALYSIS BY END USE
53. 6.53 SOUTH KOREA MARKET ANALYSIS BY INDICATION
54. 6.54 SOUTH KOREA MARKET ANALYSIS BY GENE TYPE
55. 6.55 SOUTH KOREA MARKET ANALYSIS BY ADMINISTRATION ROUTE
56. 6.56 SOUTH KOREA MARKET ANALYSIS BY END USE
57. 6.57 MALAYSIA MARKET ANALYSIS BY INDICATION
58. 6.58 MALAYSIA MARKET ANALYSIS BY GENE TYPE
59. 6.59 MALAYSIA MARKET ANALYSIS BY ADMINISTRATION ROUTE
60. 6.60 MALAYSIA MARKET ANALYSIS BY END USE
61. 6.61 THAILAND MARKET ANALYSIS BY INDICATION
62. 6.62 THAILAND MARKET ANALYSIS BY GENE TYPE
63. 6.63 THAILAND MARKET ANALYSIS BY ADMINISTRATION ROUTE
64. 6.64 THAILAND MARKET ANALYSIS BY END USE
65. 6.65 INDONESIA MARKET ANALYSIS BY INDICATION
66. 6.66 INDONESIA MARKET ANALYSIS BY GENE TYPE
67. 6.67 INDONESIA MARKET ANALYSIS BY ADMINISTRATION ROUTE
68. 6.68 INDONESIA MARKET ANALYSIS BY END USE
69. 6.69 REST OF APAC MARKET ANALYSIS BY INDICATION
70. 6.70 REST OF APAC MARKET ANALYSIS BY GENE TYPE
71. 6.71 REST OF APAC MARKET ANALYSIS BY ADMINISTRATION ROUTE
72. 6.72 REST OF APAC MARKET ANALYSIS BY END USE
73. 6.73 SOUTH AMERICA MARKET ANALYSIS
74. 6.74 BRAZIL MARKET ANALYSIS BY INDICATION
75. 6.75 BRAZIL MARKET ANALYSIS BY GENE TYPE
76. 6.76 BRAZIL MARKET ANALYSIS BY ADMINISTRATION ROUTE
77. 6.77 BRAZIL MARKET ANALYSIS BY END USE
78. 6.78 MEXICO MARKET ANALYSIS BY INDICATION
79. 6.79 MEXICO MARKET ANALYSIS BY GENE TYPE
80. 6.80 MEXICO MARKET ANALYSIS BY ADMINISTRATION ROUTE
81. 6.81 MEXICO MARKET ANALYSIS BY END USE
82. 6.82 ARGENTINA MARKET ANALYSIS BY INDICATION
83. 6.83 ARGENTINA MARKET ANALYSIS BY GENE TYPE
84. 6.84 ARGENTINA MARKET ANALYSIS BY ADMINISTRATION ROUTE
85. 6.85 ARGENTINA MARKET ANALYSIS BY END USE
86. 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY INDICATION
87. 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY GENE TYPE
88. 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY ADMINISTRATION ROUTE
89. 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY END USE
90. 6.90 MEA MARKET ANALYSIS
91. 6.91 GCC COUNTRIES MARKET ANALYSIS BY INDICATION
92. 6.92 GCC COUNTRIES MARKET ANALYSIS BY GENE TYPE
93. 6.93 GCC COUNTRIES MARKET ANALYSIS BY ADMINISTRATION ROUTE
94. 6.94 GCC COUNTRIES MARKET ANALYSIS BY END USE
95. 6.95 SOUTH AFRICA MARKET ANALYSIS BY INDICATION
96. 6.96 SOUTH AFRICA MARKET ANALYSIS BY GENE TYPE
97. 6.97 SOUTH AFRICA MARKET ANALYSIS BY ADMINISTRATION ROUTE
98. 6.98 SOUTH AFRICA MARKET ANALYSIS BY END USE
99. 6.99 REST OF MEA MARKET ANALYSIS BY INDICATION
100. 6.100 REST OF MEA MARKET ANALYSIS BY GENE TYPE
101. 6.101 REST OF MEA MARKET ANALYSIS BY ADMINISTRATION ROUTE
102. 6.102 REST OF MEA MARKET ANALYSIS BY END USE
103. 6.103 KEY BUYING CRITERIA OF HEALTHCARE
104. 6.104 RESEARCH PROCESS OF MRFR
105. 6.105 DRO ANALYSIS OF HEALTHCARE
106. 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE
107. 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
108. 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE
109. 6.109 HEALTHCARE, BY INDICATION, 2024 (% SHARE)
110. 6.110 HEALTHCARE, BY INDICATION, 2024 TO 2035 (USD Billion)
111. 6.111 HEALTHCARE, BY GENE TYPE, 2024 (% SHARE)
112. 6.112 HEALTHCARE, BY GENE TYPE, 2024 TO 2035 (USD Billion)
113. 6.113 HEALTHCARE, BY ADMINISTRATION ROUTE, 2024 (% SHARE)
114. 6.114 HEALTHCARE, BY ADMINISTRATION ROUTE, 2024 TO 2035 (USD Billion)
115. 6.115 HEALTHCARE, BY END USE, 2024 (% SHARE)
116. 6.116 HEALTHCARE, BY END USE, 2024 TO 2035 (USD Billion)
117. 6.117 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 North America MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY INDICATION, 2025-2035 (USD Billion)
  2. 7.2.2 BY GENE TYPE, 2025-2035 (USD Billion)
  3. 7.2.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  4. 7.2.4 BY END USE, 2025-2035 (USD Billion)
2. 7.3 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.3.1 BY INDICATION, 2025-2035 (USD Billion)
  2. 7.3.2 BY GENE TYPE, 2025-2035 (USD Billion)
  3. 7.3.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  4. 7.3.4 BY END USE, 2025-2035 (USD Billion)
3. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
  1. 7.4.1 BY INDICATION, 2025-2035 (USD Billion)
  2. 7.4.2 BY GENE TYPE, 2025-2035 (USD Billion)
  3. 7.4.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  4. 7.4.4 BY END USE, 2025-2035 (USD Billion)
4. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.5.1 BY INDICATION, 2025-2035 (USD Billion)
  2. 7.5.2 BY GENE TYPE, 2025-2035 (USD Billion)
  3. 7.5.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  4. 7.5.4 BY END USE, 2025-2035 (USD Billion)
5. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
  1. 7.6.1 BY INDICATION, 2025-2035 (USD Billion)
  2. 7.6.2 BY GENE TYPE, 2025-2035 (USD Billion)
  3. 7.6.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  4. 7.6.4 BY END USE, 2025-2035 (USD Billion)
6. 7.7 UK MARKET SIZE ESTIMATES; FORECAST
  1. 7.7.1 BY INDICATION, 2025-2035 (USD Billion)
  2. 7.7.2 BY GENE TYPE, 2025-2035 (USD Billion)
  3. 7.7.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  4. 7.7.4 BY END USE, 2025-2035 (USD Billion)
7. 7.8 France MARKET SIZE ESTIMATES; FORECAST
  1. 7.8.1 BY INDICATION, 2025-2035 (USD Billion)
  2. 7.8.2 BY GENE TYPE, 2025-2035 (USD Billion)
  3. 7.8.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  4. 7.8.4 BY END USE, 2025-2035 (USD Billion)
8. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
  1. 7.9.1 BY INDICATION, 2025-2035 (USD Billion)
  2. 7.9.2 BY GENE TYPE, 2025-2035 (USD Billion)
  3. 7.9.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  4. 7.9.4 BY END USE, 2025-2035 (USD Billion)
9. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
  1. 7.10.1 BY INDICATION, 2025-2035 (USD Billion)
  2. 7.10.2 BY GENE TYPE, 2025-2035 (USD Billion)
  3. 7.10.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  4. 7.10.4 BY END USE, 2025-2035 (USD Billion)
10. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
  1. 7.11.1 BY INDICATION, 2025-2035 (USD Billion)
  2. 7.11.2 BY GENE TYPE, 2025-2035 (USD Billion)
  3. 7.11.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  4. 7.11.4 BY END USE, 2025-2035 (USD Billion)
11. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.12.1 BY INDICATION, 2025-2035 (USD Billion)
  2. 7.12.2 BY GENE TYPE, 2025-2035 (USD Billion)
  3. 7.12.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  4. 7.12.4 BY END USE, 2025-2035 (USD Billion)
12. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.13.1 BY INDICATION, 2025-2035 (USD Billion)
  2. 7.13.2 BY GENE TYPE, 2025-2035 (USD Billion)
  3. 7.13.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  4. 7.13.4 BY END USE, 2025-2035 (USD Billion)
13. 7.14 China MARKET SIZE ESTIMATES; FORECAST
  1. 7.14.1 BY INDICATION, 2025-2035 (USD Billion)
  2. 7.14.2 BY GENE TYPE, 2025-2035 (USD Billion)
  3. 7.14.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  4. 7.14.4 BY END USE, 2025-2035 (USD Billion)
14. 7.15 India MARKET SIZE ESTIMATES; FORECAST
  1. 7.15.1 BY INDICATION, 2025-2035 (USD Billion)
  2. 7.15.2 BY GENE TYPE, 2025-2035 (USD Billion)
  3. 7.15.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  4. 7.15.4 BY END USE, 2025-2035 (USD Billion)
15. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
  1. 7.16.1 BY INDICATION, 2025-2035 (USD Billion)
  2. 7.16.2 BY GENE TYPE, 2025-2035 (USD Billion)
  3. 7.16.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  4. 7.16.4 BY END USE, 2025-2035 (USD Billion)
16. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
  1. 7.17.1 BY INDICATION, 2025-2035 (USD Billion)
  2. 7.17.2 BY GENE TYPE, 2025-2035 (USD Billion)
  3. 7.17.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  4. 7.17.4 BY END USE, 2025-2035 (USD Billion)
17. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
  1. 7.18.1 BY INDICATION, 2025-2035 (USD Billion)
  2. 7.18.2 BY GENE TYPE, 2025-2035 (USD Billion)
  3. 7.18.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  4. 7.18.4 BY END USE, 2025-2035 (USD Billion)
18. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
  1. 7.19.1 BY INDICATION, 2025-2035 (USD Billion)
  2. 7.19.2 BY GENE TYPE, 2025-2035 (USD Billion)
  3. 7.19.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  4. 7.19.4 BY END USE, 2025-2035 (USD Billion)
19. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
  1. 7.20.1 BY INDICATION, 2025-2035 (USD Billion)
  2. 7.20.2 BY GENE TYPE, 2025-2035 (USD Billion)
  3. 7.20.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  4. 7.20.4 BY END USE, 2025-2035 (USD Billion)
20. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.21.1 BY INDICATION, 2025-2035 (USD Billion)
  2. 7.21.2 BY GENE TYPE, 2025-2035 (USD Billion)
  3. 7.21.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  4. 7.21.4 BY END USE, 2025-2035 (USD Billion)
21. 7.22 South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.22.1 BY INDICATION, 2025-2035 (USD Billion)
  2. 7.22.2 BY GENE TYPE, 2025-2035 (USD Billion)
  3. 7.22.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  4. 7.22.4 BY END USE, 2025-2035 (USD Billion)
22. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
  1. 7.23.1 BY INDICATION, 2025-2035 (USD Billion)
  2. 7.23.2 BY GENE TYPE, 2025-2035 (USD Billion)
  3. 7.23.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  4. 7.23.4 BY END USE, 2025-2035 (USD Billion)
23. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
  1. 7.24.1 BY INDICATION, 2025-2035 (USD Billion)
  2. 7.24.2 BY GENE TYPE, 2025-2035 (USD Billion)
  3. 7.24.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  4. 7.24.4 BY END USE, 2025-2035 (USD Billion)
24. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
  1. 7.25.1 BY INDICATION, 2025-2035 (USD Billion)
  2. 7.25.2 BY GENE TYPE, 2025-2035 (USD Billion)
  3. 7.25.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  4. 7.25.4 BY END USE, 2025-2035 (USD Billion)
25. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.26.1 BY INDICATION, 2025-2035 (USD Billion)
  2. 7.26.2 BY GENE TYPE, 2025-2035 (USD Billion)
  3. 7.26.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  4. 7.26.4 BY END USE, 2025-2035 (USD Billion)
26. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.27.1 BY INDICATION, 2025-2035 (USD Billion)
  2. 7.27.2 BY GENE TYPE, 2025-2035 (USD Billion)
  3. 7.27.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  4. 7.27.4 BY END USE, 2025-2035 (USD Billion)
27. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
  1. 7.28.1 BY INDICATION, 2025-2035 (USD Billion)
  2. 7.28.2 BY GENE TYPE, 2025-2035 (USD Billion)
  3. 7.28.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  4. 7.28.4 BY END USE, 2025-2035 (USD Billion)
28. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
  1. 7.29.1 BY INDICATION, 2025-2035 (USD Billion)
  2. 7.29.2 BY GENE TYPE, 2025-2035 (USD Billion)
  3. 7.29.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  4. 7.29.4 BY END USE, 2025-2035 (USD Billion)
29. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.30.1 BY INDICATION, 2025-2035 (USD Billion)
  2. 7.30.2 BY GENE TYPE, 2025-2035 (USD Billion)
  3. 7.30.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  4. 7.30.4 BY END USE, 2025-2035 (USD Billion)
30. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.31.1
1. 7.32 ACQUISITION/PARTNERSHIP
7.32.1

Certified Researchers

Customize Report

Healthcare Market Segmentation

Healthcare By Indication (USD Billion, 2025-2035)

Leber Congenital Amaurosis
Retinitis Pigmentosa
Stargardt Disease
Choroideremia

Healthcare By Gene Type (USD Billion, 2025-2035)

Adeno-Associated Virus
Lentivirus
Messenger RNA
DNA

Healthcare By Administration Route (USD Billion, 2025-2035)

Intravitreal Injection
Subretinal Injection
Intravitreous Injection

Healthcare By End Use (USD Billion, 2025-2035)

Hospitals
Specialty Clinics
Research Laboratories

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Features	License Type
Features	Single User	Multiuser License	Enterprise User
Price	$4,950	$5,950	$7,250
Maximum User Access Limit	1 User	Upto 10 Users	Unrestricted Access Throughout the Organization
Free Customization	✓	✓	✓
Direct Access to Analyst	✓	✓	✓
Deliverable Format	✓	✓	✓
Platform Access	✗	✗	✓
Discount on Next Purchase	10%	15%	15%
Printable Versions	✗	✗	✓